

Bis-(1*H*-2-benzopyran-1-one) derivatives: Synthesis and antimicrobial evaluation

POONAM KUMAR KOPPULA^a and NALINI PUROHIT^{b,*}

^aSchool of Science and Education, Navrachana University, Vadodara 391 410, India

^bDepartment of Chemistry, Faculty of Science, The Maharaja Sayajirao University of Baroda, Vadodara 390 002, India

e-mail: nalinipurohit22@gmail.com

MS received 20 May 2013; revised 4 September 2013; accepted 5 September 2013

Abstract. The aim of the present study was to synthesize isocoumarin heterocycles and to elucidate the potential role of these compounds as biological active agents. A new series of isocoumarin derivatives containing two six-membered lactone rings is reported. 3-Aroyl-substituted isocoumarins (**3**) obtained by condensing 2-carboxy benzaldehyde (**1**) with bromoacetophenone derivatives (**2**) was further reacted with different aromatic aldehydes (**4**) affording bis-(1*H*-2-benzopyran-1-one) derivatives (**5**). This short review compiles examples of most promising antibacterial, antifungal and analgesic bis-(1*H*-2-benzopyran-1-one) derivatives. The products were characterized on the basis of analytical and spectral (IR, ¹HNMR, C¹³NMR, Mass) data. The biological activity study revealed that all compounds showed promising activities and bis-(1*H*-2-benzopyran-1-one) derivatives (**5**) were found to be more active than 3-aryol-substituted isocoumarins (**3**).

Keywords. 2-Carboxy benzaldehyde; 3-aryol isocoumarin; bis-(1*H*-2-benzopyran-1-one) derivatives; antibacterial activity; antifungal activity; analgesic activity.

1. Introduction

Among the 877 new molecule entities worldwide introduced as drugs during 1981–2002, 61% can be traced to or were inspired by natural products.¹ These include natural products, natural product derivatives, synthetic compounds with natural product derived pharmacophores and synthetic compounds designed on the basis of knowledge gained from a natural product.² Similarly, isocoumarins are an important class of naturally occurring biologically active lactones, originating from a variety of natural sources, with multiple biological activities.

Several articles dealing with the varied physiological activities of isocoumarin derivatives have been published, describing their anti-allergic, antimicrobial, immunomodulatory, cytotoxic, antifungal, anti-inflammatory and anti-angiogenic action. For the past many years, the study of biological activities of isocoumarin derivatives has been the aim of many researchers.^{3–11}

In our earlier studies,^{12–14} we found an increase in the bacteriological properties of isocoumarins on introducing various substituted alkyl/acyl, aroyl and

aminomethyl linkages at different positions in isocoumarin nucleus. Also, the structure activity relationships of isocoumarins have revealed that the mere presence of isocoumarin moiety in any compound itself is an essential feature of their pharmacological action.¹⁵

Furthermore, in recent decades, an increased incidence of microbial infection has been observed as a consequence of the growing number of immunocompromised patients and the frequent use of antibacterial and cytotoxic drugs.

Despite the fact that the isocoumarin skeleton is found in a variety of natural products, the dimerization of isocoumarin itself has not been investigated. There exist only few relevant examples in literature,^{16–18} related to the dimerization of coumarins and its different derivatives along with their biological applications.

Based on the wide spectrum of biological profile of isocoumarins, and their increasing importance in pharmaceutical and biological fields, and in continuation of our ongoing research on biologically active heterocycles, it was thought to be interest to accommodate two identical isocoumarin moieties in a single molecular framework to synthesize some new heterocyclic compounds with potential biological activity.

*For correspondence

2. Experimental

2.1 Materials and methods

Reagents and solvents used in this study were of analytical grade and used without further purification. Melting points were determined in open capillaries and are uncorrected. Purity of the compounds was checked by Thin Layer Chromatography (TLC) on silica gel GF254 plates using UV/iodine as visualizing agent and Merk's silica gel (60–120 mesh) was used for column chromatographic purification. Infrared spectra were recorded on Fourier Transform Infra Red (FTIR) Perkin–Elmer spectrophotometer using potassium bromide optics. ^1H NMR and ^{13}C NMR spectra were recorded on a Bruker spectrometer (400 MHz) using Tetramethylsilane (TMS) as internal standard and chemical shifts are given in ppm. Mass spectra were obtained using Thermo Scientific Corporation, DSQ II Mass Spectrometer. Elemental analyses were carried out on Perkin–Elmer C, H, N, S Analyser (Model-2400). Bromo acetophenone derivatives were prepared by literature method.¹⁹ Antibacterial activity of newly synthesized compounds was tested *in vitro* in bacterial strains, *Staphylococcus aureus* (clinical strain) and *Escherichia coli* (DH5 alpha) using serial agar dilution (cup plate method)²⁰ and Dimethylformamide (DMF) were used as positive controls. Antifungal activity was performed *in vitro* against fungal strains *Fusarium pallidroseum* and *Colletotrichum capsici*, using Potato Dextrose Agar Medium (Poisoned Food Technique).²¹ Analgesic activity of the compounds was determined *in vivo* by tail flick method.²² Gum acacia (2%) as control and analgin drug as standard were used.

2.2 General method for synthesis of 3-aryl-1H-2-benzopyran-1-one (3a–3f)

2-Carboxy benzaldehyde (1 g, 0.006 mol) **1**, 2-bromo-1-(4-bromo-phenyl)-ethanone (1.85 g, 0.006 mol) **2**, K_2CO_3 (2.00 g, 0.012 mol) and ethyl methyl ketone (10 ml) were taken in a round bottom flask and refluxed for 10–12 h. Solvent was then removed, water added and extracted with ethyl acetate. Solvent layer was first washed with sodium bicarbonate and then with water and dried over anhydrous Na_2SO_4 . After removal of solvent, the crude product was purified by column chromatography using petroleum ether (60–80°C)-ethyl acetate.

2.2a 3-(4'-Bromo-benzoyl)-1H-2-benzopyran-1-one (3a): White crystals, mp: 171°C; 76.0% yield; IR (KBr, ν , cm^{-1}): 1735 (γ lactone), 1600 (C=O), 680 (C-Br); Anal. Calcd $\text{C}_{16}\text{H}_9\text{O}_3\text{Br}$ (328.9 g): C, 58.37; H, 2.73; Found: C, 58.42; H, 3.06; ^1H NMR (CDCl_3) δ

7.42 (s, 1H, CH), 7.63–7.91 (m, 7H, aromatic protons), 8.44 (dd, 1H, CH); ^{13}C NMR (CDCl_3) δ 187 (C=O, ketone), 164 (C=O, lactone), 142 (=C-O), 129 (C-Br), 132.3 (CH), 131.9 (CH), 136 (C), 115.6 (C), 136.5 (C), 128 (C), 130 (CH), 127.8 (CH), 133.6 (CH), 126 (CH); ms: m/z : 328.97 (M^+ , 35%), 249(10), 174(19) and 146(100).

2.2b 3-(4'-Hydroxy-benzoyl)-1H-2-benzopyran-1-one (3b): White crystals, mp: 180°C; 64.2% yield; IR (KBr, ν , cm^{-1}): 1730 (γ lactone), 1610 (C=O), 3528 (OH); Anal. Calcd $\text{C}_{16}\text{H}_{10}\text{O}_4$ (266.0 g): C, 72.18; H, 3.75; Found: C, 72.00; H, 3.18; ^1H NMR (CDCl_3) δ 5.57 (s, 1H, OH), 7.61 (s, 1H, CH), 7.04–7.86 (m, 7H, aromatic protons), 8.34 (d, 1H, CH); ^{13}C NMR (CDCl_3) δ 187 (C=O, ketone), 163 (C=O, lactone), 141.6 (=C-O), 163 (C-OH), 116 (CH), 131 (CH), 136 (C), 116 (C), 136.5 (C), 128 (C), 130 (CH), 127.8 (CH), 133.6 (CH), 126 (CH); ms: m/z : 266.04 (M^+ , 48%), 185(10), 145(60) and 121(100).

2.2c 3-(2', 4'-Dihydroxy-benzoyl)-1H-2-benzopyran-1-one (3c): Pinkish white crystals, mp: 116°C; 44.6% yield; IR (KBr, ν , cm^{-1}): 1733 (γ lactone), 1602 (C=O), 3556 (OH); Anal. Calcd $\text{C}_{16}\text{H}_{10}\text{O}_5$ (282.0 g): C, 68.08; H, 3.54; Found: C, 68.37; H, 4.08; ^1H NMR (CDCl_3) δ 5.51 (s, 1H, OH), 5.87 (s, 1H, OH), 7.59 (s, 1H, CH), 6.74–7.72 (m, 6H, aromatic protons), 8.29 (d, 1H, CH); ^{13}C NMR (CDCl_3) δ 187 (C=O, ketone), 163 (C=O, lactone), 141 (=C-O), 165 (C-OH), 159 (C-OH), 108 (CH), 103 (CH), 132 (CH), 116.5 (C), 116 (C), 136.5 (C), 128.3 (C), 130 (CH), 127.6 (CH), 133.6 (CH), 126 (CH); ms: m/z : 282 (M^+ , 26%), 264(8), 238(15), 173(47), 146(65), 137(60) and 57(83).

2.2d 3-(4'-Methoxy-benzoyl)-1H-2-benzopyran-1-one (3d): Yellow crystals, mp: 134°C; 62.8% yield; IR (KBr, ν , cm^{-1}): 1728 (γ lactone), 1556 (C=O), 1083 (OCH_3); Anal. Calcd $\text{C}_{17}\text{H}_{12}\text{O}_4$ (280.0 g): C, 72.85; H, 4.28; Found: C, 73.24; H, 3.94; ^1H NMR (CDCl_3) δ 3.95 (s, 3H, OCH_3), 7.42 (s, 1H, CH), 7.64–7.93 (m, 7H, aromatic protons), 8.43 (dd, 1H, CH); ^{13}C NMR (CDCl_3) δ 187 (C=O, ketone), 163 (C=O, lactone), 141.7 (=C-O), 168 (C- OCH_3), 114.6 (CH), 131 (CH), 56 (CH_3), 129 (C), 116 (C), 136.5 (C), 128 (C), 130 (CH), 127.8 (CH), 133.6 (CH), 126 (CH); ms: m/z : 280 (M^+ , 42), 252(54), 249(20), 145(74), 135(59) and 118(13).

2.2e 3-(Benzoyl)-1H-2-benzopyran-1-one (3e): White crystals, mp: 64°C; 65.1% yield; IR (KBr, ν , cm^{-1}): 1703 (γ lactone), 1629 (C=O); Anal. Calcd $\text{C}_{22}\text{H}_{14}\text{O}_3$ (326.0 g): C, 80.98; H, 4.29; Found: C, 81.29; H, 4.31;

^1H NMR (CDCl_3) δ 7.42 (s, 1H, CH), 7.33–7.90 (m, 12H, aromatic protons), 8.41 (dd, 1H, CH); ^{13}C NMR (CDCl_3) δ 187 (C=O, ketone), 163 (C=O, lactone), 141.6 (=C-O), 134 (CH), 129 (CH), 130 (CH), 137 (C), 116 (C), 136.7 (C), 128.1 (C), 130 (CH), 127.6 (CH), 133 (CH), 126.1 (CH); ms: m/z : 325 ($\text{M}^+ - 1$, 45%), 300(62), 272(7), 221(21), 195(72), 174(27) and 146(95).

2.2f 3-(Dibenzofuran-3-carbonyl)-1H-2-benzopyran-1-one (**3f**): White crystals, mp: 110°C; 65.6% yield; IR (KBr, ν , cm^{-1}): 1720 (γ lactone), 1543 (C=O), 1253 (CO); Anal. Calcd $\text{C}_{22}\text{H}_{12}\text{O}_4$ (340.0 g): C, 77.64; H, 3.52; Found: C, 77.51; H, 4.01; ^1H NMR (CDCl_3) δ 7.76 (s, 1H, CH), 7.20–8.00 (m, 10H, aromatic protons), 8.45 (d, 1H, CH); ^{13}C NMR (CDCl_3) δ 187 (C=O, ketone), 163 (C=O, lactone), 141 (=C-O), 132.8 (C), 113 (CH), 124.4 (CH), 122 (CH), 156 (C), 133.8 (C), 145 (C), 106.9 (C), 121 (CH), 123 (CH), 124 (CH), 111.8 (CH), 116 (C), 136.5 (C), 128 (C), 130 (CH), 127.8 (CH), 133.6 (CH), 126 (CH); ms: m/z : 340 (M^+ , 12%), 312(31), 174(3), 168(10) and 146(82).

2.3 General method for synthesis of bis-(1H-2-benzopyran-1-one) derivatives (**5a–5m**)

A mixture of 3-aryl isocoumarin **3b** (1 g, 0.0037 mol) was dissolved in ethanol and heated on water bath to get a clear solution. p-chlorobenzaldehyde **4** (0.264 g, 0.0018 mol) was added to this hot solution and refluxed for 18–20 h at 80°C. After the reaction was over, the solvent was distilled off and product recrystallized from ethanol.

2.3a 4, 4'-(4-Chlorobenzylidene)-bis-[3-(4'-hydroxy benzoyl)-1H-2-benzopyran-1-one] (**5a**): Pale white crystals, mp: 200°C; 74.9% yield; IR (KBr, ν , cm^{-1}): 1710 (γ lactone), 1495 (C=O), 3112 (OH); Anal. Calcd $\text{C}_{39}\text{H}_{23}\text{O}_8\text{Cl}$ (654.5 g): C, 71.61; H, 3.51; Found: C, 71.95; H, 3.14; ^1H NMR (CDCl_3) δ 5.75 (s, 1H, CH), 6.90–8.10 (m, 18H, aromatic protons), 8.39 (d, 2H, CH), 9.95 (s, 2H, OH); ^{13}C NMR (CDCl_3) δ 163 (C=O, lactone), 186 (C=O, ketone), 134 (=C-O), 163 (C-OH), 39 (CH), 116 (CH), 131 (CH), 129 (C), 126 (C), 137 (C), 128.3 (C), 130 (CH), 127.6 (CH), 133.6 (CH), 126 (CH), 130.6 (C-Cl), 129 (CH), 130 (CH), 135.8 (C); ms: m/z : 480(7%), 410(5), 390(16), 375(24), 298(42), 266(50), 145(27), 121(49), 118(19) and 77(61).

2.3b 4, 4'-(Benzylidene)-bis-[3-(4'-hydroxy benzoyl)-1H-2-benzopyran-1-one] (**5b**): White crystals, mp: 197°C; 70.0% yield; IR (KBr, ν , cm^{-1}): 1718 (γ lactone), 1519 (C=O), 3252 (OH); Anal. Calcd $\text{C}_{39}\text{H}_{24}\text{O}_8$

(620.0 g): C, 75.48; H, 3.87; Found: C, 75.03; H, 4.17; ^1H NMR (CDCl_3) δ 3.65 (s, 2H, OH), 5.85 (s, 1H, CH), 6.98–7.99 (m, 19H, aromatic protons), 8.27 (d, 2H, CH); ^{13}C NMR (CDCl_3) δ 163 (C=O, lactone), 187 (C=O, ketone), 134.3 (=C-O), 163.1 (C-OH), 38.7 (CH), 116 (CH), 131 (CH), 129.3 (C), 125.5 (C), 136.4 (C), 128.1 (C), 130 (CH), 127.3 (CH), 133.4 (CH), 126.1 (CH), 125.4(C-H), 128 (CH), 129 (CH), 137.8 (C); ms: m/z : 620 (M^+ , 8%), 603(4), 577(26), 551(42), 509(8), 423(7), 368(38), 264(48) and 121(46).

2.3c 4, 4'-(4-Nitrobenzylidene)-bis-[3-(4'-hydroxy benzoyl)-1H-2-benzopyran-1-one] (**5c**): White crystals, mp: 198°C; 68.2% yield; IR (KBr, ν , cm^{-1}): 1701 (γ lactone), 1664 (C=O), 3428 (OH), 1486 (NO_2); Anal. Calcd $\text{C}_{39}\text{H}_{23}\text{O}_{10}\text{N}$ (665.0 g): C, 70.37; H, 3.45; N, 2.10; Found: C, 70.71; H, 3.92; N, 2.53; ^1H NMR (CDCl_3) δ 6.70 (s, 1H, CH), 7.54–8.19 (m, 18H, aromatic protons), 8.27 (d, 2H, CH) 9.35 (s, 2H, OH); ^{13}C NMR (CDCl_3) δ 163 (C=O, lactone), 187 (C=O, ketone), 134.3 (=C-O), 163.1 (C-OH), 38.5 (CH), 116.2 (CH), 131.1 (CH), 129.1 (C), 125.7 (C), 136.5 (C), 128 (C), 130 (CH), 127.3 (CH), 133.6 (CH), 126.1 (CH), 145.4(C- NO_2), 123 (CH), 130 (CH), 143.8 (C); ms: m/z : 663 ($\text{M}^+ - 2$, 2%), 619(8), 525(1), 479(2), 405(1), 266(30), 145(28) and 121(100).

2.3d 4, 4'-(4-Methoxybenzylidene)-bis-[3-(4'-hydroxy benzoyl)-1H-2-benzopyran-1-one] (**5d**): Yellow crystals, mp: 200°C; 72.0% yield; IR (KBr, ν , cm^{-1}): 1683 (γ lactone), 1624 (C=O), 3315 (OH), 1246 (OCH_3); Anal. Calcd $\text{C}_{40}\text{H}_{26}\text{O}_9$ (650.0 g): C, 73.84; H, 4.00; Found: C, 74.21; H, 4.38; ^1H NMR (CDCl_3) δ 3.84 (s, 3H, OCH_3), 7.41 (s, 1H, CH), 7.36–8.01 (m, 18H, aromatic protons), 8.35 (d, 2H, CH) 8.77 (s, 2H, OH); ^{13}C NMR (CDCl_3) δ 163 (C=O, lactone), 187 (C=O, ketone), 134.3 (=C-O), 163.1 (C-OH), 38.5 (CH), 116.2 (CH), 131.1 (CH), 129.1 (C), 125.7 (C), 136.5 (C), 128 (C), 130 (CH), 127.3 (CH), 133.6 (CH), 126.1 (CH), 159(O-CH_3), 56 (C - OCH_3), 114 (CH), 130 (CH), 130 (C); ms: m/z : 649 ($\text{M}^+ - 1$, 2%), 616 (1), 588 (3), 560 (5), 529(2), 406(9), 383(13), 329(10), 280(42), 145(24) and 135(84).

2.3e 4, 4'-(4-Nitrobenzylidene)-bis-[3-(4'-bromo benzoyl)-1H-2-benzopyran-1-one] (**5e**): Yellow crystals, mp: 144°C; 68.2% yield; IR (KBr, ν , cm^{-1}): 1720 (γ lactone), 1543 (C=O), 1446 (NO_2), 526 (C-Br); Anal. Calcd $\text{C}_{39}\text{H}_{21}\text{O}_8\text{NBr}_2$ (776.8 g): C, 59.18; H, 2.65; N, 1.77; Found: C, 58.97; H, 2.74; N, 2.05; ^1H NMR (CDCl_3) δ 7.50 (s, 1H, CH), 7.31–8.10 (m, 18H, aromatic protons), 8.44 (d, 2H, CH); ^{13}C NMR (CDCl_3) δ 163 (C=O, lactone), 187 (C=O, ketone), 134.3

(=C-O), 129 (C-Br), 38.6 (CH), 132.2 (CH), 131.8 (CH), 135.7(C), 125.5 (C), 136.5 (C), 128.1 (C), 130 (CH), 127.6 (CH), 133.6 (CH), 126 (CH), 145 (C -NO₂), 123.3 (CH), 130 (CH), 144 (C); ms: *m/z*: 776.8 (M⁺, 1%), 617(1), 571(2), 540(12), 447.9(17), 435(3), 407(2), 328.9(48), 187(20), 183.9(51), 146(45), and 77(75).

2.3f 4, 4'-(4-Hydroxybenzylidene)-bis-[3-(4'-bromo benzoyl)-1H-2-benzopyran-1-one] (**5f**): Yellow crystals, mp: 150°C; 69.0% yield; IR (KBr, *v*, cm⁻¹): 1700 (γ lactone), 1643 (C=O), 3226 (OH), 580 (C-Br); Anal. Calcd C₃₉H₂₂O₇Br₂ (761.8 g): C, 61.43; H, 2.88; Found: C, 61.72; H, 3.12; ¹H NMR (CDCl₃) δ 6.03 (s, 1H, OH), 7.51 (s, 1H, CH), 7.30–8.15 (m, 18H, aromatic protons), 8.38 (d, 2H, CH); ¹³C NMR (CDCl₃) δ 163 (C=O, lactone), 187 (C=O, ketone), 134.3 (=C-O), 128.9 (C-Br), 33 (CH), 132.3 (CH), 131.9 (CH), 135 (C), 126 (C), 137 (C), 128.3 (C), 130 (CH), 127.6 (CH), 133.4 (CH), 126 (CH), 154 (C-OH), 116 (CH), 130.5 (CH), 131 (C); ms: *m/z*: 761.8 (M⁺, 1%), 602(4), 585(6), 508(8), 432.9(15), 392(25), 183.9(10), 146(67) and 118(43).

2.3g 4, 4'-(Benzylidene)-bis-[3-(4'-bromo benzoyl)-1H-2-benzopyran-1-one] (**5g**): White crystals, mp: 176°C; 62.7% yield; IR (KBr, *v*, cm⁻¹): 1689 (γ lactone), 1652 (C=O), 632 (C-Br); Anal. Calcd C₃₉H₂₂O₆Br₂ (745.8 g): C, 62.75; H, 2.94; Found: C, 63.18; H, 3.36; ¹H NMR (CDCl₃) δ 7.41 (s, 1H, CH), 7.44–8.15 (m, 18H, aromatic protons), 8.45 (d, 2H, CH); ¹³C NMR (CDCl₃) δ 163.2 (C=O, lactone), 186.8 (C=O, ketone), 134 (=C-O), 128.7 (C-Br), 32.6 (CH), 132 (CH), 131.9 (CH), 136 (C), 125.8 (C), 136.5 (C), 128.3 (C), 130 (CH), 128 (CH), 133.4 (CH), 126.1 (CH), 125.5(CH), 128.3 (CH), 129 (CH), 137.7 (C); ms: *m/z*: 745.8 (M⁺, 4%), 665.9(7), 509(1), 481(29), 376(11), 483.9(5), 416.9(32), 328.9(31), 183.9(41) and 146(60).

2.3h 4, 4'-(4-Nitrobenzylidene)-bis-[3-(4'-methoxy benzoyl)-1H-2-benzopyran-1-one] (**5h**): Yellow crystals, mp: 128°C; 54.3% yield; IR (KBr, *v*, cm⁻¹): 1710 (γ lactone), 1682 (C=O), 1065 (OCH₃), 1486 (NO₂); Anal. Calcd C₄₁H₂₇O₁₀N (693.0 g): C, 70.99; H, 3.89; N, 2.02; Found: C, 71.23; H, 4.07; N, 1.94; ¹H NMR (CDCl₃) δ 3.74 (s, 6H, OCH₃), 7.55 (s, 1H, CH), 7.00–7.90 (m, 18H, aromatic protons), 8.20 (d, 2H, CH); ¹³C NMR (CDCl₃) δ 163 (C=O, lactone), 187 (C=O, ketone), 134.3 (=C-O), 168 (C-OCH₃), 56 (O-CH₃), 38.8 (CH), 115 (CH), 130.8 (CH), 129 (C), 125.5 (C), 136.5 (C), 128.3 (C), 130 (CH), 127.6 (CH), 133.6 (CH), 126 (CH), 145.5 (C -NO₂), 123.3 (CH),

130.1 (CH), 143.5 (C); ms: *m/z*: 693 (M⁺, 16%), 662(10), 525(10), 479(13), 405(15), 280(36), 145(29) and 135(87).

2.3i 4, 4'-(4-Hydroxybenzylidene)-bis-[3-(4'-methoxy benzoyl)-1H-2-benzopyran-1-one] (**5i**): Yellow crystals, mp: 90°C; 61.7% yield; IR (KBr, *v*, cm⁻¹): 1735 (γ lactone), 1600 (C=O), 3189 (OH), 1163 (OCH₃); Anal. Calcd C₄₁H₂₈O₉ (664.0 g): C, 74.09; H, 4.21; Found: C, 73.86; H, 4.65; ¹H NMR (CDCl₃) δ 3.99 (s, 6H, OCH₃), 7.35 (s, 1H, CH), 7.04–7.79 (m, 18H, aromatic protons), 8.39 (dd, 2H, CH) 12.70 (s, 1H, OH); ¹³C NMR (CDCl₃) δ 163 (C=O, lactone), 187 (C=O, ketone), 134.3 (=C-O), 167.8 (C-OCH₃), 56 (O-CH₃), 38.7 (CH), 114.5 (CH), 130.7 (CH), 129 (C), 125.8 (C), 137(C), 128 (C), 130.2 (CH), 127.6 (CH), 134 (CH), 126.2 (CH), 154 (CH), 115 (CH), 130.5 (CH), 130.3 (C); ms: *m/z*: 662 (M⁺-2, 3%), 647(1), 585(19), 508(11), 497(14), 384(24), 392(30), 145(36) and 135(49).

2.3j 4, 4'-(4-Methoxybenzylidene)-bis-[3-(4'-methoxy benzoyl)-1H-2-benzopyran-1-one] (**5j**): Yellow crystals, mp: 134°C; 60.0% yield; IR (KBr, *v*, cm⁻¹): 1735 (γ lactone), 1626 (C=O), 1258 (OCH₃); Anal. Calcd C₄₂H₃₀O₉ (678.0 g): C, 74.33; H, 4.42; Found: C, 74.47; H, 4.68; ¹H NMR (CDCl₃) δ 4.16 (s, 9H, OCH₃), 7.45 (s, 1H, CH), 7.31–7.85 (m, 18H, aromatic protons), 8.40 (d, 2H, CH); ¹³C NMR (CDCl₃) δ 163 (C=O, lactone), 187 (C=O, ketone), 134.3 (=C-O), 167.4 (C-OCH₃), 56.2 (O -CH₃), 39 (CH), 114.6 (CH), 130.7 (CH), 129 (C), 125.5 (C), 136.5 (C), 128.3 (C), 130 (CH), 127.6 (CH), 133.6 (CH), 126 (CH), 158 (C-OCH₃), 57 (O-CH₃), 114 (CH), 130.2 (CH), 130 (C); ms: *m/z*: 678 (M⁺, 17%), 398(2), 280(27), 146(70), 135(41) and 118(52).

2.3k 4, 4'-(4-Nitrobenzylidene)-bis-[3-(2', 4'-dihydroxy benzoyl)-1H-2-benzopyran-1-one] (**5k**): Yellow crystals, mp: 75°C; 34.4% yield; IR (KBr, *v*, cm⁻¹): 1702 (γ lactone), 1682 (C=O), 3320 (OH), 1590 (NO₂); Anal. Calcd C₃₉H₂₃O₁₂N (697.0 g): C, 67.14; H, 3.29; N, 2.00; Found: C, 66.29; H, 3.57; N, 1.84; ¹H NMR (CDCl₃) δ 7.42 (s, 1H, CH), 6.82–8.19 (m, 16H, aromatic protons), 8.46 (d, 2H, CH), 11.60 (s, 2H, OH), 11.80 (s, 2H, OH) ; ¹³C NMR (CDCl₃) δ 163 (C=O, lactone), 187 (C=O, ketone), 134.3 (=C-O), 165 (C-OH), 160 (C-OH), 33 (CH), 108.8 (CH), 103.4 (CH), 132 (CH), 116.5 (C), 125.5 (C), 136.5 (C), 128.3 (C), 130 (CH), 127.6 (CH), 133.6 (CH), 126 (CH), 145.4 (C -NO₂), 123.5 (CH), 130.1 (CH), 143.9 (C); ms: *m/z*: 698 (M⁺+1, 6%), 680(23), 617(8), 558(20), 540(34), 453(27), 415(20), 264(48), 173(39), 146(43) and 137(44).

2.31 4, 4'-(4-Hydroxybenzylidene)-bis-[3-(2', 4'-dihydroxy benzoyl)-1H-2-benzopyran-1-one] (**5l**): White crystals, mp: 126°C; 38.7% yield; 1742 (γ lactone), 1706 (C=O), 3310 (OH); Anal. Calcd C₃₉H₂₅O₁₁ (669.0 g): C, 69.95; H, 3.73; Found: C, 70.21; H, 3.70; ¹H NMR (CDCl₃) δ 7.47 (s, 1H, CH), 6.81–7.79 (m, 17H, aromatic protons), 8.38 (d, 2H, CH), 9.84 (s, 1H, OH), 12.53 (s, 2H, OH), 12.70 (s, 2H, OH); ¹³C NMR (CDCl₃) δ 163 (C=O, lactone), 187 (C=O, ketone), 134.3 (=C-O), 165 (C-OH), 160 (C-OH), 32 (CH), 109 (CH), 103 (CH), 132.5 (CH), 117 (C), 125.5 (C), 136.5 (C), 128.3 (C), 130 (CH), 127.6 (CH), 133.6 (CH), 126 (CH), 154 (C-OH), 115.5 (CH), 130.5 (CH), 130.4 (C); ms: *m/z*: 668 (M⁺–1, 1%), 618 (2), 541(6), 436(16), 387(45), 331(22), 282(17), 173(40), 146(57) and 77(92).

2.3m 4, 4'-(4-Methoxybenzylidene)-bis-[3-(2', 4'-dihydroxy benzoyl)-1H-2-benzopyran-1-one] (**5m**): Yellow crystals, mp: 144°C; 35.2% yield; 1705 (γ lactone), 1695 (C=O), 3568 (OH); Anal. Calcd C₄₀H₂₆O₁₁ (683.0 g): C, 70.27; H, 3.95; Found: C, 69.84; H, 3.78; ¹H NMR (CDCl₃) δ 3.83 (s, 3H, OCH₃), 5.79 (s, 4H, OH), 7.42 (s, 1H, CH), 6.60–7.57 (m, 16H, aromatic protons), 8.42 (d, 2H, CH); ¹³C NMR (CDCl₃) δ 163 (C=O, lactone), 187 (C=O, ketone), 134.3 (=C-O), 164.5 (C-OH), 159.9 (C-OH), 33.3 (CH), 108.8 (CH), 103.4 (CH), 132 (CH), 116.5 (C), 125.5 (C), 136.5 (C), 128.3 (C), 130 (CH), 127.6 (CH), 133.6 (CH), 126 (CH), 159 (C–OCH₃), 56 (O–CH₃), 114 (CH), 130.2 (CH), 130 (C); ms: *m/z*: 683 (M⁺, 11%), 666 (8), 618(32), 541(10), 495(18), 439(5), 401(6) and 146(33).

3. Results and discussion

3.1 Chemistry

2-Carboxy benzaldehyde was refluxed with different substituted bromo acetophenones in presence of anhy.

K₂CO₃ for 10–12 h, taking ethyl methyl ketone as solvent to get 3-aryl isocoumarins (figure 1). Characterization of synthesized compounds was done by IR and NMR spectral studies. All the compounds in **3a–f** show absorption at 1735–1700 cm⁻¹ for lactonic carbonyl and 1629–1543 cm⁻¹ for ketonic carbonyl. Presence of C-Br in **3a** and –OH group in **3b** and **3c** is confirmed by signals at 680 cm⁻¹ and 3528–3556 cm⁻¹ (br.), respectively. NMR spectrum of **3a–3d** shows signals at δ 7.04–8.00 (m, 9H) for vinylic as well as aromatic protons, at δ 3.95 (s, OCH₃, 3H), with the proton at 8th position showing a characteristic doublet at around δ 8.34–8.44. Mass spectrum of **3a** (MW 328.9 g) shows M⁺ peak at *m/z* 328.97, base peak at *m/z* 146 for C₉O₂H₆(isocoumarin moiety without any substitution) and *m/z* 174 for M⁺–C₆H₄Br. Mass spectrum of **3d** (MW 266) shows M⁺ peak at *m/z* 266.04, base peak at *m/z* 121 for M⁺–COC₆H₄OH and *m/z* 146 for C₉O₂H₆(isocoumarin moiety without any substitution).

3-Aroyl isocoumarins **3** formed were then condensed with different aryl aldehydes **4** in the ratio 2:1 in ethanol to get bis-(1H-2-benzopyran-1-one) derivatives **5a–m** (figure 2). **5a** shows IR signals for –OH, lactonic carbonyl and ketonic carbonyl, respectively. NMR spectrum of **5a** shows signals at δ 5.75–7.50 (s, 1H, CH), 6.90–8.10 (m, 18H, aromatic protons), 8.25–8.45 (d, 2H, CH) 10.00–10.50 (s, 2H, OH). Mass spectrum of **5a** gives *m/z* peak at 480, 410, 390, 375, 298, 266, 145, 121, 118 and 77.

3.2 Pharmacology

Some of the prepared compounds **3a–b**, **d**, **5b–d** were tested *in vitro* against bacterial strains, *Staphylococcus aureus* (Gram-positive) and *Escherichia coli* (Gram-negative) using serial agar dilution (cup plate method)²⁰ and fungal strains of *Fusarium pallidoseum* and *Chaetonium* using Potato Dextrose Agar medium (Poisoned Food Technique),²¹ respectively.





Figure 1. Synthetic pathway for the preparation of compounds **3a–f**.



R = OH, R' = H, R'' = Cl (**5a**)

R = OH, R' = H, R'' = H (**5b**)

R = OH, R' = H, R'' = NO₂ (**5c**)

R = OH, R' = H, R'' = OCH₃ (**5d**)

R = Br, R' = H, R'' = NO₂ (**5e**)

R = Br, R' = H, R'' = OH (**5f**)

R = Br, R' = H, R'' = H (**5g**)

R = OCH₃, R' = H, R'' = NO₂ (**5h**)

R = OCH₃, R' = H, R'' = OH (**5i**)

R = OCH₃, R' = H, R'' = OCH₃ (**5j**)

R = OH, R' = OH, R'' = NO₂ (**5k**)

R = OH, R' = OH, R'' = OH (**5l**)

R = OH, R' = OH, R'' = OCH₃ (**5m**)

Figure 2. Synthetic pathway for the preparation of compounds **5a–m**.

Table 1. Antimicrobial activity.

Compound	Zone of inhibition (mm)		% Growth of inhibition	
	<i>S. aureus</i>	<i>E. coli</i>	<i>F. pallidorozeum</i>	<i>Chaetonium</i>
3a	16	14	13.75	6.83
3b	15	11	29.60	17.76
3d	11	14	48.97	43.10
5b	15	14	64.87	70.60
5c	17	14	57.34	66.64
5d	15	15	64.08	70.00
Control (DMF)	0	10	-	-
Ampicillin	15	5	-	-

Table 2. Analgesic activity.

Compound	Dose (mg/kg) body weight	Average (\pm SE) reaction time (s) time after drug treatment (min)			
		0	30	60	90
Control	50	3.01	3.20	3.10	3.02
Standard	50	3.09	5.25	7.75	9.00
3a	50	1.32	3.28	3.69	4.77
3b	50	2.46	3.00	3.04	3.88
3d	50	3.62	3.97	4.01	5.35
5b	50	4.00	4.53	5.98	7.44
5c	50	3.53	4.20	5.68	6.52
5d	50	3.41	4.73	5.05	6.93

The zone of inhibition of all compounds was found to show moderate activity against Gram-negative i.e., *Escherichia coli* bacteria and significant activity was seen with all compounds against Gram-positive bacteria *S. aureus*. Among all, excellent result was with **5c** where $-\text{NO}_2$ group is substituted to isocoumarin moiety apart from two $-\text{OH}$ groups attached to aroyl group. Promising effect was with **3a**, where $-\text{Br}$ was substituted to aroyl group. Presence of hydroxyl group in aroyl moiety and $-\text{NO}_2$ in isocoumarin moiety has enhanced antibacterial activity.

The pattern of the result for antifungal activity of the tested compounds was quite different from antibacterial activity. Compound **3a–b,d** were found to be weakly or moderately active against both fungi where only one isocoumarin moiety was present, but the compounds **5b–d** where two isocoumarin moieties exist, showed almost double the activity among all compounds. The conclusion might be drawn that isocoumarin moiety plays an important role in showing antifungal activity rather than the substituent group present in it as seen in antibacterial activity.

The results of antimicrobial screening of selected new compounds are summarized in table 1.

Analgesic activity of the compounds was determined by tail flick method²² on mice of either sex. Gum acacia (2%) was used as control, Analgin was the standard drug. 3-Aroyl isocoumarins fare badly in reaction time when compared to the standard drug. The response time is tremendous, almost equivalent to standard drug when two six-membered lactone rings are present together, irrespective of the other groups present in them. This shows that the lactone ring in itself is useful in for biological applications.

The results are shown in table 2.

4. Conclusion

In conclusion, new bis-(1*H*-2-benzopyran-1-one) derivatives were prepared from easily accessible starting materials in a single step. The preliminary *in vitro* test results of these compounds against the four studied micro-organisms such as *Staphylococcus aureus*, *Escherichia coli*, *Fusarium pallidorozeum* and *Chaetonium* shows significant activity. All the tested compounds showed good analgesic action also.

Acknowledgements

Authors are grateful to Sun Pharmaceutical Industries Ltd. Baroda and SAIF, Punjab University for NMR spectra analysis; and also to Prof. Anjana Desai, Mrs. Aparna S of Microbiology Department, Prof. Arun Arya, Head, Department of Botany, The Maharaja Sayajirao University of Baroda for Antimicrobial screening, and to Mr. G Paramesh, Gulbarga University for analgesic activity.

References

1. Newman D J, Cragg G M and Snader K M 2003 *J. Nat. Prod.* **66** 1022
2. Cedrik Garino, Frederic Bihel, Nicolas Pietrancosta, Younes Laras, Gilles Quelever, Irene Woo, Peter Klein, Jenny Bain, Jean-Luc Boucherd and Jean-Louis Krausa 2005 *Bioorg. Med. Chem. Lett.* **15** 135
3. Higgins C A, Delbederi Z, McGarel K, Mills T, McGrath O, Feutren-Burton S, Watters W, Armstrong P, Johnston P G, Waugh D and Berg H van den 2009 *Bioconjugate Chem.* **20** 1737
4. Huang Y F, Li L H, Tian L, Qiao L, Hua H M and Pei Y H 2006 *J. Antibiot.* **59** 355
5. Di Stasi L C, Camuesco D, Nieto A, Vilegas W, Zarzuelo A and Galvez J 2004 *Planta Med.* **70** 315
6. Kontogiorgis C A and Hadjipavlou-Litina D J 2005 *J. Med. Chem.* **48** 6400
7. Li J, Ding Y, Li X C, Ferreira D, Khan S, Smillie T and Khan I A 2009 *J. Nat. Prod.* **72** 983
8. Ozcan S, Sahin E and Balci M 2007 *Tetrahedron Lett.* **48** 2151
9. Endringer D C, Guimaraes K G, Kondratyuk T P, Pezzuto J M and Braga F C 2008 *J. Nat. Prod.* **71** 1082
10. Bogdanov M G, Kandinska M I, Dimitrova D B, Gocheva B T and Palamareva M D 2007 *Z. Naturforsch* **62** 477
11. Kongsaree P, Prabpai S, Sriubolmas N, Vongvein C and Wiyakrutta S 2003 *J. Nat. Prod.* **66** 709
12. Yadav P and Purohit N 2013 *J. Chem. Sci.* **125** 165
13. Yadav P and Purohit N 2011 *Indian J. Pharm. Sci.* **73** 171
14. Yadav P and Purohit N 2012 *Der Pharmacia Lettre* **4** 565
15. Yuan Haiqing, Junker Bernd, Helquist Paul and Taylor Richard E 2004 *Curr. Org. Synth.* **1** 1
16. Khalil T, Hannaneh H, Alireza K, Manouchehr M and Nosrat O M 2012 *J. Serb. Chem. Soc.* **77** 407
17. Davorka Z, Samija M, Damjan M, Janez P, Mario C, Ante N, Erik De C, Jan B and Mladen M 2011 *Molecules* **16** 6023
18. Irena K, Georgi M, Tzvetomira T and Margarita K 2006 *Bioinorg. Chem. Appl.* **2006** 1
19. Furniss B S, Smith P W G, Tatchell A R and Hannaford A J 1989 *Vogel's textbook of practical organic chemistry*, 5th ed., (London, UK: Longman Scientific and Technical) p. 1016, E.L.B.S
20. Indu M N, Hatha A A M, Abirosh C, Harsha U and Vivekanandan G 2006 *Braz. J. Microbiol.* **37** 153
21. Nene Y L and Thapliyal P L 1979 *Fungicide in plant disease control* (New Delhi: Oxford and IBH Pub. Co.) 507
22. Kulkarni S K 1993 *Handbook of experimental pharmacology* (Delhi: Vallabh Prakashan) 50